Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11970541 | 0.83 | CYP19A1 (0.41) | CYP19A1CYP3A4 | |
| SCHEMBL14676435 | 0.78 | USP2 (0.34) | CYP19A1CYP3A4 | |
| SCHEMBL25218748 | 0.75 | CA2 (0.38) | — | |
| SCHEMBL30307739 | 0.75 | CA2 (0.38) | — | |
| SCHEMBL30307646 | 0.74 | IDH1 (0.35) | — | |
| SCHEMBL28956111 | 0.74 | IDH1 (0.35) | — | |
| SCHEMBL11970656 | 0.74 | CYP19A1 (0.45) | CYP19A1CYP3A4 | |
| SCHEMBL30310137 | 0.74 | CYP19A1 (0.45) | CYP19A1CYP3A4 | |
| SCHEMBL26105611 | 0.74 | CYP19A1 (0.45) | CYP19A1CYP3A4 | |
| SCHEMBL26102426 | 0.74 | CYP19A1 (0.45) | CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315881-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-10-23 | — | — | US | disclosed |
| EP-2736330-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019682-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315881-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | CYP19A1 410/4885CYP3A4 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.